Sorin Group Announces Freedom Solo FDA Study Results at the AATS 2014 Scientific Sessions

Freedom SoloTM stentless valve shows outstanding hemodynamic and clinical performance in multicenter heart valve study

AATS 2014

TORONTO--()--Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, is proud to announce the results of its trial on the Freedom Solo for approval on the US market presented at the 94th Annual Meeting of American Association for Thoracic Surgery (AATS) in Toronto, Canada.

In the trial presented on April 30, ‘One-Year Outcome on 616 Patients Receiving a Stentless Bioprosthesis: Results from a European Multicentre Study’ researchers evaluated the safety and effectiveness of the Freedom Solo stentless bioprosthesis in patients requiring aortic valve replacement (AVR) with or without combined cardiac procedures.

One-year outcomes reported by M.Thalmann et.al. showed good clinical results, with low mortality (thirty day mortality and late mortality were respectively 1.5% and 4.5%), low morbidity rate and excellent hemodynamic performance (MPG and EOA at 1 year were 7.2 ± 4 mmHg and 1.5 ± 0.5 mm/cm2).

“This study confirms the safety and effectiveness of a stentless aortic valve that has demonstrated an outstanding hemodynamic performance, durability and ease of implant through years of clinical performance in Europe,” said Markus Thalmann, M.D., Krankenhaus Hietzing, Wien, Austria, principal investigator of the European arm and of the U.S. FDA study, which included patients from 18 selected and experienced centers in Europe.

Freedom Solo, a truly stentless and a fully biological aortic heart valve with no synthetic material, has been in clinical use since 2004. This unique bioprosthesis was designed to respect the aortic root anatomy and ensure a physiological blood flow through the annulus.

“Exhibiting excellent hemodynamic performance and proven long-term clinical outcomes, Sorin Group bioprosthetic valves are the choice of cardiac surgeons worldwide. Sorin heart valves remain at the forefront of innovation and uphold our tradition of clinical excellence,” said Michel Darnaud, President Cardiac Surgery Business Unit, Sorin Group.

About Sorin Group

Sorin Group (www.sorin.com) is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, Sorin Group focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement prostheses) and Cardiac Rhythm Management (pacemakers, defibrillators and non invasive monitoring to diagnose arrhythmias and deliver anti-arrhythmia therapies as well as cardiac resynchronization devices for heart failure treatment). Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.

For more information, please visit www.sorin.com

Contacts

Sorin Group
Gabriele Mazzoletti, +39 02 69969785
Mobile: +39 348 9792201
Director, Corporate Communications
gabriele.mazzoletti@sorin.com
or
Sorin Group
Francesca Rambaudi, +39 02 69969716
Director, Investor Relations
investor.relations@sorin.com

Release Summary

Sorin Group announces the results of its trial on the Freedom Solo for approval on the US market presented at the 94th Annual Meeting of American Association for Thoracic Surgery (AATS) in Toronto

Sharing

Contacts

Sorin Group
Gabriele Mazzoletti, +39 02 69969785
Mobile: +39 348 9792201
Director, Corporate Communications
gabriele.mazzoletti@sorin.com
or
Sorin Group
Francesca Rambaudi, +39 02 69969716
Director, Investor Relations
investor.relations@sorin.com